[PDF][PDF] Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in …

…, L Kostakoglu, K Scheidhauer… - Journal of clinical …, 2007 - researchgate.net
… Wiseman, Lale Kostakoglu, Klemens Scheidhauer, Andreas Buck, Ralph Naumann,
Karoline Spaepen, Rodney J. Hicks, Wolfgang A. Weber, Sven N. … Wiseman, Lale …

Metabolic activity and clinical features of primary ganglioneuromas

…, D Harms, J Grebe, K Scheidhauer… - … Journal of the …, 2001 - Wiley Online Library
BACKGROUND Ganglioneuroma (GN) is considered by most to be a benign tumor of neural
crest origin. It may evolve from differentiating neuroblastoma or may be diagnosed as …

Spect/ct

…, BJ Krause, K Herrmann, K Scheidhauer… - Journal of Nuclear …, 2008 - Soc Nuclear Med
In view of the commercial success of integrated PET/CT scanners, there is an increasing
interest in comparable SPECT/CT systems. SPECT in combination with CT enables a direct …

[HTML][HTML] First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE …

…, T Sauerbruch, M Savin, K Scheidhauer… - The Lancet …, 2017 - thelancet.com
Background Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent
therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver …

Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

…, U Feine, R Lietzenmayer, K Scheidhauer… - European journal of …, 1999 - Springer
Original article Page 1 Abstract. The aim of this multicentre study was to evaluate the clinical
significance of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) …

Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

MR Weihrauch, D Re, K Scheidhauer… - Blood, The Journal …, 2001 - ashpublications.org
Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD)
after completed therapy, and the discrimination between active tumor tissue and fibrotic …

Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration …

…, C D'Alessandria, I Rauscher, K Scheidhauer… - The Journal of …, 2016 - auajournals.org
Purpose : We report our initial clinical experience with β -emitting 177 Lu-PSMA-I&T ( 177
Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic …

Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions

…, K Herrmann, CH Pfob, K Scheidhauer… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …

[HTML][HTML] Clinical applications of FDG PET and PET/CT in head and neck cancer

A Al-Ibraheem, A Buck, BJ Krause, K Scheidhauer… - Journal of …, 2009 - hindawi.com
18F-FDG PET plays an increasing role in diagnosis and management planning of head and
neck cancer. Hybrid PET/CT has promoted the field of molecular imaging in head and neck …

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide

DJ Kwekkeboom, EP Krenning, K Scheidhauer… - …, 2009 - karger.com
Dik J. Kwekkeboom a Eric P. Krenning a Klemens Scheidhauer b Val Lewington c Rachida
Lebtahi d Ashley Grossman e Pavel Vitek f Anders Sundin g Ursula Plöckinger h and the …